ALS LIMITED (ALQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALQ

ALQ - ALS LIMITED

FNArena Sector : Industrial Sector Contractors & Engineers
Year End: March
GICS Industry Group : Commercial & Professional Services
Debt/EBITDA: 2.92
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

ALS Ltd provides laboratory and testing services across the mining, industrial and life sciences sector. It operates in over 65 countries. Formerly Campbell Brothers Ltd it first listed in 1952 and changed name to ALS in 2012.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$15.30

15 Apr
2025

0.160

OPEN

$15.18

1.06%

HIGH

$15.37

960,812

LOW

$15.13

TARGET
$16.83 10.0% upside
Franking for last dividend paid out: 30%
OTHER COMPANIES IN THE SAME SECTOR
3DA . AVD . BSA . CG1 . CLG . CVL . CWY . CXL . DOW . DUR . EGL . EGN . EVS . FLC . IPG . LBL . MAD . PPK . RWL . SDV . SHA . SND . SSM . SYL . VEE . VNT .
FNARENA'S MARKET CONSENSUS FORECASTS
ALQ: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 2.7 63.3 xxx
DPS (cps) xxx 39.2 38.1 xxx
EPS Growth xxx - 95.4% 100.0% xxx
DPS Growth xxx - 1.3% - 2.8% xxx
PE Ratio xxx N/A 23.7 xxx
Dividend Yield xxx N/A 2.5% xxx
Div Pay Ratio(%) xxx 1468.2% 60.2% xxx

Dividend yield today if purchased 3 years ago: 3.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.62

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 27/11 - ex-div 18.90c (franking 30%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx2.7
DPS All xxxxxxxxxxxxxxx39.2
Sales/Revenue xxxxxxxxxxxxxxx2,461.6 M
Book Value Per Share xxxxxxxxxxxxxxx244.4
Net Operating Cash Flow xxxxxxxxxxxxxxx359.2 M
Net Profit Margin xxxxxxxxxxxxxxx0.52 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx1.01 %
Return on Invested Capital xxxxxxxxxxxxxxx0.48 %
Return on Assets xxxxxxxxxxxxxxx0.36 %
Return on Equity xxxxxxxxxxxxxxx1.01 %
Return on Total Capital xxxxxxxxxxxxxxx15.86 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx17.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx318 M
Long Term Debt xxxxxxxxxxxxxxx1,554 M
Total Debt xxxxxxxxxxxxxxx1,872 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx300 M
Price To Book Value xxxxxxxxxxxxxxx5.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx151.7 M
Capex % of Sales xxxxxxxxxxxxxxx6.16 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,624 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx371 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx46 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

07/03/2025

1

Buy

$18.00

17.65%

On the back of an improved outlook for commodity factors, Bell Potter upgrades earnings for ALS Ltd.

The analyst notes junior equity raisings advanced 53% year-on-year in February, representing the fifth consecutive month of annual growth.

Typically, this precedes changes in junior activity by six to nine months and suggests an inflection point for the cycle in mid-2025.

Life sciences updates from global peers indicate strong organic growth in 4Q24 in environmental food testing, notably in the company's markets, the analyst highlights.

Bell Potter lifts EPS estimates by 5% for FY26 and FY27. Target price rises to $18 from $17.30, with no change to the Buy rating.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 38.00 cents and EPS of 62.70 cents.
Bell Potter forecasts a full year FY26 dividend of 45.20 cents and EPS of 74.50 cents.

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

21/11/2024

3

Downgrade to Neutral from Overweight

$14.40

-5.88%

ALS Ltd's 1H25 core profit of $152m came in slightly ahead of consensus at $150m, driven by stable performance in Life Sciences and resilience in Commodities margins despite volatile geochemistry sampling flows, notes Jarden.

Commodities division EBIT margins remained robust at 31%, driven by larger miners contributing 70-75% of testing flows, though the broker observes sampling flow growth declined by -0.5% year-on-year.

Life Sciences achieved growth through organic expansion and contributions from recent M&A (including Nuvisan), highlights the analyst.

Jarden downgrades ALS Ltd to Neutral from Overweight, citing limited near-term earnings catalysts, and increases the target price to $14.40 from $14.25.

FORECAST
Jarden forecasts a full year FY25 dividend of 37.40 cents and EPS of 63.50 cents.
Jarden forecasts a full year FY26 dividend of 42.50 cents and EPS of 71.80 cents.
Access Extra Coverage Research History >

ALQ STOCK CHART

FNArena News on ALQ

1
Rudi’s View: Best Buys In Copper, Small Caps, Tech, Healthcare, And More

Mar 20 2025 - Rudi's View
2
Rudi’s View: Post February Conviction Calls

Mar 13 2025 - Rudi's View
3
Australian Broker Call *Extra* Edition – Mar 10, 2025

Mar 10 2025 - Daily Market Reports
4
Rudi’s View: Best Buys & Convictions For 2025

Jan 16 2025 - Rudi's View
5
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View

Latest Industrial Sector Contractors & Engineers News

1
Southern Cross Electrical Adding Fire As Fuel

Apr 04 2025 - Small Caps
2
Rising Margins Boost ALS’ Favourable Outlook

Nov 22 2024 - Australia
3
A Golden Era For Engineering Services?

Oct 30 2024 - Feature Stories
4
How the Tides Turn: Water Scarcity And Services In Australia

Oct 14 2024 - ESG Focus
5
Transitory Headwinds For ALS

Sep 30 2024 - Australia
6
Cleanaway’s Efforts Not Wasted

Sep 23 2024 - Australia
7
IPD Group’s Future Remains Electrifying

Sep 06 2024 - Small Caps
8
It’s Electric Under The Southern Cross

Jul 24 2024 - Small Caps
9
Ventia Services: Unique Mix Of Growth & Defence

Jul 09 2024 - Small Caps
10
In The Bin; ASX-Listed Waste Companies

Nov 02 2023 - Australia